Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Inmune Bio (INMB) over the last 8 years, with Q3 2025 value amounting to -$5.4 million.

  • Inmune Bio's Cash from Operations rose 2215.86% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.7 million, marking a year-over-year decrease of 1909.66%. This contributed to the annual value of -$33.4 million for FY2024, which is 17833.33% down from last year.
  • Per Inmune Bio's latest filing, its Cash from Operations stood at -$5.4 million for Q3 2025, which was up 2215.86% from -$7.4 million recorded in Q2 2025.
  • Inmune Bio's 5-year Cash from Operations high stood at -$1.1 million for Q1 2023, and its period low was -$11.1 million during Q4 2024.
  • Its 5-year average for Cash from Operations is -$6.1 million, with a median of -$5.7 million in 2021.
  • In the last 5 years, Inmune Bio's Cash from Operations surged by 8712.92% in 2023 and then tumbled by 55521.47% in 2024.
  • Over the past 5 years, Inmune Bio's Cash from Operations (Quarter) stood at -$9.8 million in 2021, then soared by 41.77% to -$5.7 million in 2022, then soared by 39.93% to -$3.4 million in 2023, then tumbled by 223.06% to -$11.1 million in 2024, then surged by 50.8% to -$5.4 million in 2025.
  • Its Cash from Operations stands at -$5.4 million for Q3 2025, versus -$7.4 million for Q2 2025 and -$6.8 million for Q1 2025.